VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | MANIFEST: CPI-0610 shows promise in myelofibrosis

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses MANIFEST (NCT02158858), an ongoing Phase II study evaluating the efficacy of the novel BET inhibitor CPI-0610 in JAK-inhibitor-naïve myelofibrosis patients. The study found that CPI-0610 is active as a monotherapy and in combination with ruxolitinib in both a salvage therapy and frontline therapy setting. High spleen volume and symptom response rates were seen in the frontline setting in particular. Almost 33% of patients experienced a reduction in bone marrow fibrosis, and an improvement in hemoglobin could be seen in anemic patients. CPI-0610 was well tolerated, with most patients only experiencing low grade adverse events that could easily be managed. A planned Phase III study aims to improve overall quality of life, duration of response and overall survival in myelofibrosis patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

John Mascarenhas, MD, has done consultancy work with Celgene/BMS, Prelude, Galecto, Promedior, Geron, Constellation and Incyte, and has received research funding from Incyte, Kartos, Roche, Promedior, Merck, Merus, Arog, CTI Biopharma, Janssen and PharmaEssentia.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter